Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enekinragene inzadenovec - Pacira BioSciences

Next Previous
Drug Profile

Enekinragene inzadenovec - Pacira BioSciences

Alternative Names: PCRX201; FX 201 - Flexion Therapeutics; GQ 203; Humantakinogene hadenovec

Latest Information Update: 23 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine
  • Developer Flexion Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Gene therapies
  • Mechanism of Action Gene transference; Interleukin-1 receptor antagonist expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Osteoarthritis

Most Recent Events

  • 31 Dec 2025 Pacira BioSciences multiple patent pending applications covering composition of matter and method of use of enekinragene inzadenovec for the treatment of degenerative disc disease in USA, Australia, Canada, China, Hong Kong, Europe, Japan and South Korea before December 2025
  • 31 Dec 2025 Pacira BioSciences multiple patent pending applications covering compositions and method of use of enekinragene inzadenovec in combination with a corticosteroid in USA, Australia, Canada, China, Europe, Hong Kong, India, Japan, South Korea, and Mexico before December 2025
  • 28 Oct 2025 Updated efficacy and adverse events data from a phase I trial in Osteoporosis released by Pacira Biosciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top